



September 1, 2021

Web Announcement 2575

Nevada Medicaid Expands Dates for 2021-2022 Respiratory Syncytial Virus (RSV) Season

Update to [Web Announcement 2559](#): Due to atypically high levels of circulating Respiratory Syncytial Virus (RSV), Nevada Medicaid will open the Synagis® coverage season on September 1, 2021. Effective immediately, Nevada Medicaid providers may submit prior authorization (PA) requests for Synagis® (palivizumab). Providers may submit claims for approved Synagis® PAs beginning September 1, 2021. Reimbursement is only authorized during the 2021-2022 Nevada RSV season from September 1, 2021, through March 31, 2022. RSV activity will be closely monitored during the seven-month time frame to determine if the season length should be adjusted.

The clinical criteria used by Nevada Medicaid for the 2021-2022 RSV season are consistent with guidance published by the American Academy of Pediatrics (AAP): 2021 – 2024 Report of the Committee on Infectious Diseases, 32nd Edition. This guidance for Synagis® use among infants and children at increased risk of hospitalization for RSV infection is available online by subscription. Providers are encouraged to review the AAP guidance.

The [Synagis® Authorization Request Form \(FA-65\)](#) has been updated for the September 1, 2021, through March 31, 2022, RSV season. The [Pharmacy Billing Manual](#) has been updated with Synagis® claim submission instructions.

For any questions, call the OptumRx Call Center for Nevada Medicaid at (855) 455-3311.